The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis

J Asthma. 2017 Apr;54(3):300-307. doi: 10.1080/02770903.2016.1212371. Epub 2016 Jul 19.

Abstract

Context: Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinophil maturation and promotes programmed cell death.

Objective: We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in patients with inadequately controlled, eosinophilic asthma.

Data sources: The search included the following databases: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register.

Study selection: A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of reslizumab for the treatment of inadequately controlled, eosinophilic asthma.

Data extraction: Two reviewers independently extracted and verified pre-defined data fields.

Results: Four publications including 5 RCTs that compared reslizumab with placebo. For the comparison of reslizumab with placebo, asthma exacerbation (odds ratio (OR) = 0.46, 95% confidence interval (CI) = 0.35 to 0.59, p <0.00001); a forced expiratory volume in 1 s (FEV1) (the standardized mean difference (SMD) = 0.16, 95%CI = 0.10 to 0.23, p <0.00001); Asthma Control Questionnaire (ACQ) score (the SMD = -0.26, 95%CI= -0.36 to -0.16, p <0.00001); blood eosinophil counts (the SMD = -475.62, 95%CI = -528.41 to -422.83, p <0.00001). Safety assessments included the proportion of individuals who withdrawn due to adverse event (AE) (OR = 0.60 95%CI = 0.38 to 1.17, p = 0.16) indicated that reslizumab was well tolerated.

Limitations: The article didn't research the safety, efficacy of reslizumab with longer term.

Conclusions: This meta-analysis indicates that reslizumab to be an effective and safe treatment for inadequately controlled, eosinophilic asthma.

Keywords: Reslizumab; asthma; eosinophilic; meta-analysis; randomized controlled trial.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Anti-Asthmatic Agents / administration & dosage
  • Anti-Asthmatic Agents / adverse effects
  • Anti-Asthmatic Agents / therapeutic use*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma / drug therapy*
  • Asthma / epidemiology*
  • Double-Blind Method
  • Eosinophilia / epidemiology*
  • Humans
  • Quality of Life*
  • Randomized Controlled Trials as Topic
  • Respiratory Function Tests

Substances

  • Anti-Asthmatic Agents
  • Antibodies, Monoclonal, Humanized
  • reslizumab